1. In this randomized controlled trial, benralizumab was noninferior for beginning remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) compared to mepolizumab. 2. Adverse events occurred in 90% and 96% of patients in the benralizumab and mepolizumab groups, respectively. Evidence Rating Level: 1 (Excellent) Study Rundown: EGPA is an inflammatory disorder with patients experiencing
The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.
The study results demonstrated that 92% of patients treated with benralizumab were able to safely reduce inhaled steroid dose, and more than 60% could stop use entirely.